Suppr超能文献

特定局部晚期宫颈癌(IB3 期、IIA2 期、IIICr 期)患者同期放化疗与根治性手术的比较:一项随机对照研究(C-CRAL 试验)的试验方案。

A comparison of concurrent chemoradiotherapy and radical surgery in patients with specific locally advanced cervical cancer (stage IB3, IIA2, IIICr): trial protocol for a randomized controlled study (C-CRAL trial).

机构信息

Department of Gynecology, Obstetrics and Gynecology Hospital of Fudan University, Shanghai, China.

Department of Radiation Oncology, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China.

出版信息

J Gynecol Oncol. 2023 Sep;34(5):e64. doi: 10.3802/jgo.2023.34.e64. Epub 2023 Jun 20.

Abstract

BACKGROUND

At present, clinical dilemma remains to be solved in terms of therapy-choices for specific locally advanced cervical cancer (LACC) patients: 1) Although concurrent chemoradiotherapy (CCRT) is recommended as the first choice for them, many patients, influenced by the Chinese culture, prefer to choose radical surgery (RS) as their primary treatment. The difference between the 2 therapies in improving patient prognosis is still unknown. 2) Laparoscopy has been questioned since the noted Laparoscopic Approach to Cervical Cancer trial. Nevertheless, clinical research on laparoscopic surgery under the strict tumor-free principle is still underway globally, therefore whether laparoscopic surgery can be used for specific LACC is also an urgent issue to be explored.

METHODS

A multi-center, randomized controlled study is designed to investigate the effect of different treatment strategies on the prognosis and quality of life (QoL) in patients with specific locally LACC. A total of 402 patients will be enrolled over a period of 3 years. Eligible patients will be randomized (3:1) to either RS group or CCRT group. Patients assigned to RS group will be randomized (1:2) to the abdominal RS group or laparoscopic RS group. All patients will then be followed-up for 5 years. The primary end point is the 2-year progression-free survival (PFS). The secondary end points include 5-year PFS, 2-year overall survival (OS), 5-year OS, adverse events caused by RS or CCRT and QoL.

TRIAL REGISTRATION

Chinese Clinical Trial Registry Identifier: ChiCTR2000041315.

摘要

背景

目前,对于特定局部晚期宫颈癌(LACC)患者的治疗选择仍存在临床困境:1)尽管同步放化疗(CCRT)被推荐为首选,但许多受中国文化影响的患者更愿意选择根治性手术(RS)作为主要治疗方法。这两种治疗方法在改善患者预后方面的差异尚不清楚。2)自从腹腔镜宫颈癌手术试验(LACC)发表以来,腹腔镜手术一直受到质疑。然而,全球仍在进行严格无瘤原则下的腹腔镜手术临床研究,因此腹腔镜手术是否可用于特定的 LACC 也是一个亟待探索的问题。

方法

设计一项多中心、随机对照研究,旨在探讨不同治疗策略对特定局部 LACC 患者预后和生活质量(QoL)的影响。研究将在 3 年内纳入 402 例患者。符合条件的患者将按 3:1 的比例随机分配至 RS 组或 CCRT 组。RS 组患者将按 1:2 的比例随机分配至开腹 RS 组或腹腔镜 RS 组。所有患者将接受 5 年随访。主要终点是 2 年无进展生存率(PFS)。次要终点包括 5 年 PFS、2 年总生存率(OS)、5 年 OS、RS 或 CCRT 相关不良事件和 QoL。

试验注册

中国临床试验注册中心注册号:ChiCTR2000041315。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c878/10482577/88b445143d3a/jgo-34-e64-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验